Popular on Rezul
- Boston Industrial Solutions Introduces Natron® UVPX Series UV-LED Curing Screen Printing Inks - 302
- Due diligence you should do before buying Florida real estate - 301
- Lake Norman Philharmonic Free Concert Opens 2025-2026 Season - 295
- New construction home built in 2025 in Clear Lake, MN - 292
- LookDeep Health and Nexus Bedside Partner to Redesign Hospital Care with Agentic AI - 274
- Phinge's Netverse to Revolutionize Home & Apartment Rental Market: Verified Platform Enhances Trust, Transparency, & Rewards for Landlords & Tenants - 267
- Two Weeks Left: Secure Your Spot at the First OpenSSL Conference 2025 in Prague - 262
- Cervey, LLC and PharmaCentra, LLC Announce Strategic Partnership to Expand Pharmacy Technology Support Across Specialty Pharmacy and PBM Services - 261
- DB Landscape Co. Brings Modern Outdoor Living to Coastal Communities - 254
- Boston Pads Surpasses 19,000 Landlord Contacts In Growing Database - 251
Similar on Rezul
- Zero-Trust Architecture: NJTRX Addresses 60% of U.S. Investors' Custody Security Concerns
- Sub-Millisecond Trading Platform: HNZLLQ Introduces Unified Gateway for Philippine Digital Asset Traders
- $2.1B Theft Losses: Bitquore Launches 1M+ TPS Platform with 95% Offline Asset Protection for U.S. Traders
- Multi-Signature Cold Storage: Keyanb Introduces Institutional-Grade Asset Protection for Chilean Crypto Traders
- NKSCX Introduces Zero-Knowledge Proof of Solvency for U.S. Traders Amid $6.5 Billion Fraud Crisis
- New Oasis International Foundation Announces Strategic Partnership Network Across 15 Countries to Advance Community-Led Economic Development
- Why Indian Game Development Companies Are Shaping the Future of Global Gaming
- Cold Storage and Proof-of-Reserves: BTXSGG Launches Institutional-Grade Asset Protection for Filipino Traders
- $150 Million Financing Initiates N A S D A Q's First Tether Gold Treasury Combining the Stability of Physical Gold with Blockchain $AURE
- $73.6M Pipeline, $10M Crypto Play & Legal Firepower: Why Investors Are Watching Cycurion (N A S D A Q: CYCU) Like a Hawk
Introducing NanoSmart™ Technology: Detecting the Medication You Take From Your Breath
Rezul News/10408464
Collaboration with MetroHealth hospitals of Cleveland, Ohio sees the world's first deployment of nGageIT Digital Health's novel breath-based NanoSmart™ and NanoSensor technology for Medication Adherence.
CLEVELAND - Feb. 11, 2019 - Rezul -- NanoSmart™ technology uses nanoparticles to digitally encode the outer layer of each oral medication, turning any oral medication into a digital object that can be tracked from your breath using a smartphone . Developed under nGageIT Digital Health's NanoSmart™ Digital Medicine technology program, this enables verified, non-intrusive, real-time medication and treatment adherence monitoring to take place.
In a collaboration with MetroHealth hospitals of Cleveland, Ohio - advocates for teaching and research – nGageIT Digital Health's NanoSmart™ technology will begin clinical validation trials with MetroHealth's primary care unit, where a target of over 10,000 patients will be engaged in their treatments through nGageIT Digital Health's NanoSmart™ adherence monitoring technology and support over a 24 month period. Treatment focus will initially concentrate on Statins, HPV, and Diabetes, however additional selective areas may also include digitizing oral oncology drugs, digital medicine for hepatitis, and other areas. The product is slated to complete validation trials in 2019.
Medication non-adherence costs the US healthcare system over $300 billion and results in 125,000 premature deaths per year, with more than 1 in 5 new prescriptions going unfilled and two-thirds of patients not taking their medications as prescribed. nGageIT Digital Health's NanoSmart™ technology and their NanoSensor adherence programs can drastically improve patient outcomes through non-intrusive adherence and treatment monitoring integrated with provider care teams. The data sent to provider care in real-time allows them to customize meaningful and timely interventions to improve outcomes.
More on Rezul News
With nGageIT Digital Health, MetroHealth primary care program administrators can perform patient treatment monitoring and see when at-risk behaviors are occurring, engaging the patients and intervening to remove treatment adherence barriers. Data from the trial will be used to further develop the NanoSmart™ technology adherence platform.
This has the potential to be especially important for oral oncology drugs, where it can be very difficult positively monitor medication adherence outside the clinic at the patients home.
"The exhaled breath offers a novel frontier in medicine for the development of non-invasive digital medicine solutions for cancer that are an easily deployable Smartphone based intervention." says Dr. Jennifer Murdoch, COO and Chief Clinical Officer of nGageIT Digital Health.
"Leveraging NanoSmart™ technology in serious disease treatment programs could potentially improve outcomes for substantial numbers of cancer patients," she explains.
"We believe this cutting-edge breath-based technology may be the cornerstone to meaningfully increasing survivorship, cures, and ultimately public health. We are looking forward to the emerging clinical data, and eager to see the results from prospective clinical and real-world trials as the program progresses."
nGageIT Digital Health is also developing a related breath-based early cancer and disease detection platform that detects cancerous and other disease states from your breath at very early stages and when it is present.
More About NanoSmart™ Technology
The US pharmaceutical industry alone forfeits an estimated $250 billion annually in potential revenue due to medication non-adherence.
nGageIT Digital Health's NanoSmart™ technology can do what no medication adherence technology can by verifying medication adherence non-intrusively and in real-time through the patient's breath.
More on Rezul News
With a single breath, the device detects the unique nanoparticle "barcode" of the drug ingested. The digital biomarker is based on nGageIT Digital Health's proprietary market-leading nanoparticle encoding library.
By understand the unique breath fingerprint of the patient, nGageIT Digital Health's breath sensor technology can also distinguish if the patient ingesting the drug is the same patient that it was prescribed to. This can be an important factor in tracking Opioid drug use, reducing counterfeit tablets and reducing drug diversion.
This enables accurate reporting of real-time treatment progress, enabling program administrators to easily flag at-risk events and intervene with patients, helping them maintain treatment adherence and increase the likelihood of successful treatment completion.
"The incorporation of relevant breath based digital medicine markers allows us to unequivocally and digitally verify the point of ingestion by the patient in a seamless programmatic fashion for providers and researchers where meaningful interventions can be made." says CEO of nGageIT Digital Health, Raj Reddy.
Hospital, healthcare, and provider systems, contract research organizations, and pharmaceutical companies can utilize nGageIT Digital Health's NanoSmart™ technology in treatment and primary care applications, treatment monitoring, and clinical trials program integration and study adherence verification.
The clinical version of the test for IUO use in prospective studies is expected to launch in 2019 with the commercial version launching in 2020.
About nGageIT Digital Health
nGageIT Digital Health (www.ngageittec.com) are pioneers in the field of digital medicine encoding and sensor technology. nGageIT Digital Health is committed to making medicine smarter to improve patient engagement, enrich insights and optimize therapeutic outcomes, resulting in lower overall system costs and improved health outcomes for populations.
For further information contact:
Raj Reddy CEO
Info@ngageittec.com
for investor inquiries email
Investor@ngageittec.com
In a collaboration with MetroHealth hospitals of Cleveland, Ohio - advocates for teaching and research – nGageIT Digital Health's NanoSmart™ technology will begin clinical validation trials with MetroHealth's primary care unit, where a target of over 10,000 patients will be engaged in their treatments through nGageIT Digital Health's NanoSmart™ adherence monitoring technology and support over a 24 month period. Treatment focus will initially concentrate on Statins, HPV, and Diabetes, however additional selective areas may also include digitizing oral oncology drugs, digital medicine for hepatitis, and other areas. The product is slated to complete validation trials in 2019.
Medication non-adherence costs the US healthcare system over $300 billion and results in 125,000 premature deaths per year, with more than 1 in 5 new prescriptions going unfilled and two-thirds of patients not taking their medications as prescribed. nGageIT Digital Health's NanoSmart™ technology and their NanoSensor adherence programs can drastically improve patient outcomes through non-intrusive adherence and treatment monitoring integrated with provider care teams. The data sent to provider care in real-time allows them to customize meaningful and timely interventions to improve outcomes.
More on Rezul News
- Silva Construction Advises Homeowners on Smart Homes and Integrated Technology
- America Anesthesia Partners Unveils New User-Friendly Website
- Hiclean Tools Releases HCX2100 Electric Pressure Washer
- What you need to know before buying a home or condo in Florida
- Bùng Nổ Ra Mắt, AALIVE Tung Gói Thưởng 68% và Dàn Game Thuần Việt Hấp Dẫn
With nGageIT Digital Health, MetroHealth primary care program administrators can perform patient treatment monitoring and see when at-risk behaviors are occurring, engaging the patients and intervening to remove treatment adherence barriers. Data from the trial will be used to further develop the NanoSmart™ technology adherence platform.
This has the potential to be especially important for oral oncology drugs, where it can be very difficult positively monitor medication adherence outside the clinic at the patients home.
"The exhaled breath offers a novel frontier in medicine for the development of non-invasive digital medicine solutions for cancer that are an easily deployable Smartphone based intervention." says Dr. Jennifer Murdoch, COO and Chief Clinical Officer of nGageIT Digital Health.
"Leveraging NanoSmart™ technology in serious disease treatment programs could potentially improve outcomes for substantial numbers of cancer patients," she explains.
"We believe this cutting-edge breath-based technology may be the cornerstone to meaningfully increasing survivorship, cures, and ultimately public health. We are looking forward to the emerging clinical data, and eager to see the results from prospective clinical and real-world trials as the program progresses."
nGageIT Digital Health is also developing a related breath-based early cancer and disease detection platform that detects cancerous and other disease states from your breath at very early stages and when it is present.
More About NanoSmart™ Technology
The US pharmaceutical industry alone forfeits an estimated $250 billion annually in potential revenue due to medication non-adherence.
nGageIT Digital Health's NanoSmart™ technology can do what no medication adherence technology can by verifying medication adherence non-intrusively and in real-time through the patient's breath.
More on Rezul News
- ARCH Dental + Aesthetics Offers Free Consultations for New Patients
- Home Inspector Proz Expands Professional Inspection Services Across South Florida
- Maisano Brothers Inc. Expands National Paving Division Into Tampa, Florida
- The Wait Is Almost Over: Jason&Kerri Kramer to Launch Blue Ridge Mountains Real Estate in Asheville
- Suk Woon "Sue" Ip of RE/MAX of Princeton Named in RealTrends Verified City Rankings for Outstanding Performance
With a single breath, the device detects the unique nanoparticle "barcode" of the drug ingested. The digital biomarker is based on nGageIT Digital Health's proprietary market-leading nanoparticle encoding library.
By understand the unique breath fingerprint of the patient, nGageIT Digital Health's breath sensor technology can also distinguish if the patient ingesting the drug is the same patient that it was prescribed to. This can be an important factor in tracking Opioid drug use, reducing counterfeit tablets and reducing drug diversion.
This enables accurate reporting of real-time treatment progress, enabling program administrators to easily flag at-risk events and intervene with patients, helping them maintain treatment adherence and increase the likelihood of successful treatment completion.
"The incorporation of relevant breath based digital medicine markers allows us to unequivocally and digitally verify the point of ingestion by the patient in a seamless programmatic fashion for providers and researchers where meaningful interventions can be made." says CEO of nGageIT Digital Health, Raj Reddy.
Hospital, healthcare, and provider systems, contract research organizations, and pharmaceutical companies can utilize nGageIT Digital Health's NanoSmart™ technology in treatment and primary care applications, treatment monitoring, and clinical trials program integration and study adherence verification.
The clinical version of the test for IUO use in prospective studies is expected to launch in 2019 with the commercial version launching in 2020.
About nGageIT Digital Health
nGageIT Digital Health (www.ngageittec.com) are pioneers in the field of digital medicine encoding and sensor technology. nGageIT Digital Health is committed to making medicine smarter to improve patient engagement, enrich insights and optimize therapeutic outcomes, resulting in lower overall system costs and improved health outcomes for populations.
For further information contact:
Raj Reddy CEO
Info@ngageittec.com
for investor inquiries email
Investor@ngageittec.com
Source: nGageIT Digital Health
Filed Under: Technology
0 Comments
Latest on Rezul News
- Colliers expands Tampa Bay industrial team with new hire Tom Quinlan
- Kramer Real Estate Earns Better Business Bureau® Accreditation With An A Rating
- $150 Million Financing Initiates N A S D A Q's First Tether Gold Treasury Combining the Stability of Physical Gold with Blockchain $AURE
- Podcast for Midlife Women Entrepreneurs Celebrates 100th Episode with Rhea Lana's Founder and CEO
- What If Help Could Come Before the Fall?
- OddsTrader Examines the NHL Presidents Trophy Curse: Why Regular-Season Success Rarely Leads to Playoff Glory
- Bookmakers Review Launches Betting Insights on NBC's "The Voice: Battle of Champions"
- Coming Up this Weekend on CNBC Mike Milligan Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- The Mogharebi Group Facilitates $34.6 Million Sale of Willow Grove Apartments in Modesto, CA
- UK Website Launches "Toy Time Machine" — Find Your Childhood Christmas Toy in One Click
- $73.6M Pipeline, $10M Crypto Play & Legal Firepower: Why Investors Are Watching Cycurion (N A S D A Q: CYCU) Like a Hawk
- Grammy award-winning Cuban-Canadian artist Alex Cuba releases his 11th studio album, "Indole"
- Thread Advisory Group Launches to Help Retailers Turn Strategy Into Lasting Results
- Phinge to Bring Verification to Online Home Services Industry: Users to Earn & Redeem Rewards for All Services on Netverse App-less Verifed Platform
- QView Medical and Eve Wellness Announce Partnership to Advance Direct-to-Consumer Breast Cancer Screening With FDA-Approved AI
- New Article Reveals Common Pricing Pitfalls in Flooring Projects — And How to Avoid Them
- Airbus Defence and Space and Omnitronics Sign MoU to Advance Interoperability in Critical Communications
- White Glove Restoration Sends "Help in Boxes" to Support Communities in Ghana
- NASA Agreements, New Ocean Exploration Applications Added to Partnerships with Defiant Space Corp and Emtel Energy USA for Solar Tech Leader: $ASTI
- Chic and Secure: The Blue Luna Debuts Stylish Keychains with Purpose